Dementias pp 137-149 | Cite as

Dementia with Lewy Bodies

  • C. Ballard
  • C. Morris
  • M. Piggott


Lewy bodies are intracytoplasmic, eosinophilic intraneuronal inclusion bodies [1]. They contain phosphorylated and non-phosphorylated microfilaments, β-crystalline, ubiquitin and proteinases [2]. They are therefore indicators of cell response to stress and markers for the degradation and excretion of abnormal proteins from the cell. Although Lewy bodies in the substantia nigra were identified as a key neuropathological element of Parkinson’s disease (PD) early in the century, the importance of cortical Lewy bodies as a feature of some cases of dementia has only recently become evident. A series of single case reports and small case series appeared in the literature between the 1960s and the mid-1980s, suggesting that Lewy bodies in the cerebral cortex could be associated with a rare form of dementia [3, 4, 5, 6]. Hospital-based postmortem series reporting consecutive dementia cases have subsequently identified cortical Lewy bodies in at least 10% of dementia sufferers [7, 8, 9, 10].


Lewy Body Dementia With Lewy Body Lewy Body Dementia Dementia With Lewy Body Patient Cortical Lewy Body 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forno LS (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (950 incidental cases). Relationship to parkinsonism. J Am Geriatr Soc 17: 557–575Google Scholar
  2. 2.
    Lowe JS, Mayer RJ, London M (1996) Pathological significance of Lewy bodies in dementia. In: McKeith EG, Perry EK (eds) Dementia with Lewy bodies. Cambridge University Press, Cambridge, pp 195–203CrossRefGoogle Scholar
  3. 3.
    Woodard JS (1962) Concentric hyaline inclusion body formation in mental disease. Analysing 27 cases. J Neuropathol Exp Neurol 21: 442–449PubMedCrossRefGoogle Scholar
  4. 4.
    Yoshimura M (1983) Cortical changes in the parkinsonian brain: a contribution to the delineation of diffuse Lewy body disease. J Neurol 229: 17–32PubMedCrossRefGoogle Scholar
  5. 5.
    Kosaka K (1978) Lewy bodies in cerebral cortex: report of 3 cases. Acta Neuropathol (Berl)42: 127–134CrossRefGoogle Scholar
  6. 6.
    Gibb WRG, Esiri MM, Lees AJ (1987) Clinical and pathological features of diffuse Lewy body disease (Lewy body dementia). Brain 100: 1131–1153CrossRefGoogle Scholar
  7. 7.
    Burns A, Jacoby R, Levy R (1990) Psychiatric phenomena in Alzheimer’s disease. Br J Psychiatry 157: 72–94PubMedCrossRefGoogle Scholar
  8. 8.
    Byrne EJ, Lennox G, Lowe J, Goodwin-Austen RB (1989) Diffuse Lewy body disease, clinical features in 15 cases. J Neurol Neurosurg Psychiatry 52: 709–717PubMedCrossRefGoogle Scholar
  9. 9.
    Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK (1990) Senile dementia of the Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95: 119–139PubMedCrossRefGoogle Scholar
  10. 10.
    Hansen LA, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathological entity. Neurology 40: 1–7PubMedCrossRefGoogle Scholar
  11. 11.
    Crystal HA, Dickson DW, Lizadi HE, et al (1990) Antemortem diagnosis of diffuse Lewy body disease. Neurology 40: 1523–1528PubMedCrossRefGoogle Scholar
  12. 12.
    McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK (1992) Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22: 911–922PubMedCrossRefGoogle Scholar
  13. 13.
    Byrne EJ, Lennox G, Goodwin-Austen LB (1991) Dementia associated with cortical Lewy bodies: proposed diagnostic criteria. Dementia 2: 283–284Google Scholar
  14. 14.
    Ballard CG, Mohan RNC, Patel A, Bannister C (1993) Idiopathic clouding of consciousness — do the patients have cortical Lewy body disease? Int J Geriatr Psychiatry 8: 571–576CrossRefGoogle Scholar
  15. 15.
    Shergill S, Mullen E, D’Ath P, Katrona C (1994) What is the clinical prevalence of Lewy body dementia. Int J Geriatr Psychiatry 9: 907–912CrossRefGoogle Scholar
  16. 16.
    Ballard CG, Saad K, Gahir M, Solis M, Coope B, Wilcock G (1995) The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry 10: 477–485CrossRefGoogle Scholar
  17. 17.
    Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, Yen SH (1991) Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 41: 1402–1409PubMedCrossRefGoogle Scholar
  18. 18.
    Bancher C, Lassman H, Budka H, Jellinger K, Grundke-Iqbal I, Iqbal K, Wiche G, Scitelberger F, Wisniewski HM (1989) An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 48: 81–93PubMedCrossRefGoogle Scholar
  19. 19.
    Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy body. J Neurophatol Exp Neurol 52: 183–191CrossRefGoogle Scholar
  20. 20.
    Masliah E, Mallory M, DeTeresa R, Alford M, Hansen L (1993) Differing patterns of aberrant neuronal sprouting in Alzheimer’s disease with and without Lewy bodies. Brain Res 617: 258–266PubMedCrossRefGoogle Scholar
  21. 21.
    Ince PG, Irving D, MacArthur F, Perry RH (1991) Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson’s disease and non-demented elderly control patients. J Neurol Sci 106: 142–152PubMedCrossRefGoogle Scholar
  22. 22.
    Wu E, Lipton RG, Dickson DW (1992) Amyloid angiopathy in diffuse Lewy body disease. Neurology 42: 2131–2135PubMedCrossRefGoogle Scholar
  23. 23.
    McKeith IG, Fairbairn AF, Bothwall RA, Moore PB, Ferrier IN, Thompson P, Perry RH (1994) An evaluation of the predictor validity and inter-rater reliability of clinical diagnostic Criteria for SDLT. Neurology 44: 872–877PubMedCrossRefGoogle Scholar
  24. 24.
    Galasko D, Katzman R, Salmon DR, Thal LJ, Hanson L (1996) Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 31: 106–175CrossRefGoogle Scholar
  25. 25.
    Klakta LA, Louis ED, Schiffer RB (1996) Psychiatric factors in diffuse Lewy body disease. Findings in 28 pathologically diagnosed cases. Neurology 47: 1148–1152CrossRefGoogle Scholar
  26. 26.
    Cummings JL (1991) Behavioural complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc 39: 708–716PubMedGoogle Scholar
  27. 27.
    Howard R, Levy R (1994) Charles-Bonnet syndrome plus complex visual hallucinations of Charles Bonnet type in late paraphrenia. Int J Geriatr Psychiatry 9: 399–404CrossRefGoogle Scholar
  28. 28.
    McShane R, Godling K, Reading M, McDonald B, Esiri MM, Hope T (1995) Prospective study of relations between cortical lewy bodies, poor eyesight and hallucinations in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 59: 185–188PubMedCrossRefGoogle Scholar
  29. 29.
    Ballard CG, O’Brien J, Coope B, Fairbairn A, Abid F, Wilcock G (1997) A prospective study of psychotic symptoms in dementia sufferers. Int Psychogeriatr 9: 57–64PubMedCrossRefGoogle Scholar
  30. 30.
    Cheng A, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry EK, Perry RH (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer’s and Parkinson’s disease. J Neurol Sci 106: 50–55PubMedCrossRefGoogle Scholar
  31. 31.
    Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology 43: 1927–1934PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen RA, Kaplan RF, Meadows ME, Wilkinson H (1994) Habituation and sensitization of the orienting response following bilateral anterior cingulotomy. Neuropsychologia 32: 609–617PubMedCrossRefGoogle Scholar
  33. 33.
    Degos JD, da Fonseca N, Gray F, Cesaro P (1993) Severe frontal syndrome associated with infarcts of the left anterior cingulate gyrus and the head of the right caudate nucleus. A clinico-pathological case. Brain 116: 1541–1548PubMedGoogle Scholar
  34. 34.
    McKeith IG, Fairbairn AF, Perry R, Thompson P, Perry EK (1992b) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305: 653–678CrossRefGoogle Scholar
  35. 35.
    Marshall EF, Perry EK, Perry RH, McKeith IG, Fairbairn AF, Thompson P (1993) Dopamine metabolism in postmortem caudate nucleus in neurdegenerative disorders. Neurosci Res Commun 14: 17–25Google Scholar
  36. 36.
    Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, Court JA, Lloyd S, Fairbairn A, Brown A, Thompson P, Perry RH (1998) Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson’s disease. Biol Psychiatry 44: 765–777PubMedCrossRefGoogle Scholar
  37. 37.
    Piggott MA, Marshall EF (1996) Neurochemical correlates of pathological and iatrogenic extrapyramidal symptoms. In: McKeith E, Perry E (eds) Recent advances in dementia with Lewy bodies. Cambridge University Press, Cambridge, pp 449–467CrossRefGoogle Scholar
  38. 38.
    Förstl H, Burns A, Luthert P, Cairns N, Levy R (1993) The Lewy body variant of Alzheimer’s disease: clinical and pathological findings. Br J Psychol 162: 385–392CrossRefGoogle Scholar
  39. 39.
    Sahgal A, Galloway PH, McKeith IG, Edwardson JA, Lloyd S (1992) A comparative study of attentional deficits in senile dementia of alzheimer’s and Lewy body types. Dementia 3: 350–354Google Scholar
  40. 40.
    Ballard C, Patel A, Oyebode F, Wilcock G (1996) Cognitive decline in patients with Alzheimer’s disease, vascular dementia and Senile dementia of Lewy body type. Age Ageing 25: 209–213PubMedCrossRefGoogle Scholar
  41. 41.
    Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261: 921–923PubMedCrossRefGoogle Scholar
  42. 42.
    Martins RN, Clarnette R, Fisher C, Broe GA, Brooks WS, Montgomery P, Gandy SE (1995) Apo E genotypes in Australia: roles in early and late onset Alzheimer’s disease and Down’s syndrome. Neuroreport 6: 1513–1516PubMedCrossRefGoogle Scholar
  43. 43.
    Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Rinnuler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer’s disease. Nat Genet 7: 180–184PubMedCrossRefGoogle Scholar
  44. 44.
    Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B (1995) Fibrillogenesis in Alzheimer’s disease of the amyloid β peptides and apolipoprotein E. Biochem J 306: 599–604PubMedGoogle Scholar
  45. 45.
    Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, Xuereb JH, Roth M, Wischik CM (1994) Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer’s disease. Am J Pathol 145: 1472–1484PubMedGoogle Scholar
  46. 46.
    Morris CM, Massey HM, Benjamin R, Leake A, Broadbent C, Griffiths M, Lamb H, Brown A, Ince PG, Tyrer S, Thompson P, McKeith IG, Edwardson JA, Perry RH, Perry EK (1996) Molecular biology of APO E alleles in Alzheimer’s and non-Alzheimer’s dementias. J Neural Transm Suppl 47: 205–218PubMedCrossRefGoogle Scholar
  47. 47.
    Koller WC, Glatt SL, Hubble JP, Paolo A, Tröster AI, Handler MS, Horvat, RT, Martin C, Schmidt K, Karst A, Wijsman EM, Yu C-E, Schellenberg GD (1995) Apolipoprotein E genotypes in Parkinson’s disease with and without dementia. Ann Neurol 37: 242–245PubMedCrossRefGoogle Scholar
  48. 48.
    Saitoh T, Xia Y, Chen X, Masliah E, Galasko D, Shults C, Thal LJ, Hansen LA, Katzman R (1995) The CYP2D6B allele is overepresented in the Lewy body variant of Alzheimer’s disease. Ann Neurol 37: 110–112PubMedCrossRefGoogle Scholar
  49. 49.
    Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537–547PubMedCrossRefGoogle Scholar
  50. 50.
    Gonzalez FJ, Skoda RC, Kimura S, Demierre A (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446PubMedCrossRefGoogle Scholar
  51. 51.
    Kurth MC, Kurth JH (1993) Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson’s disease. Am J Med Genet 48: 166–168PubMedCrossRefGoogle Scholar
  52. 52.
    Kamboh MI, Shanghera DK, Ferrel RE, DeKosky ST (1995) APO E4-associated Alzheimer’s disease risk modified by αl-antichymotrypsin polymorphism. Nature Genet 10: 486–488PubMedCrossRefGoogle Scholar
  53. 53.
    Wragg M, Hutton M, Talbot C (1996) Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer’s disease. Alzheimer’s Disease Collaborative Group. Lancet 347: 509–512PubMedCrossRefGoogle Scholar
  54. 54.
    Wilcock GK (1990) Tetrohydro amino acridine and Alzheimer’s disease. BMJ 300: 939Google Scholar
  55. 55.
    Levy R, Eagger S, Griffiths M (1994) Lewy bodies and response to tacrine. Lancet 343: 176PubMedCrossRefGoogle Scholar
  56. 56.
    Schneider LS, Pollock VE, Lyness SA (1990) A meta analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38: 553–563PubMedGoogle Scholar
  57. 57.
    Auzou P, Cote L, Fahn S (1995) Clozapine Parkinson’s disease. Lancet 345: 516–517Google Scholar
  58. 58.
    Lee H, Cooney JM, Lewlor BA (1994) Case report: the use of risperidone, an atypical neuroleptin Lewy body disease. Int J Geriatr Psychiatry 9: 415–417CrossRefGoogle Scholar
  59. 59.
    McKeith IG, Ballard CG, Harrison RWS (1995) Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 346: 699PubMedCrossRefGoogle Scholar
  60. 60.
    Cummings JL, Gorman DG, Shapira J (1993) Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry 33: 536–541PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • C. Ballard
  • C. Morris
  • M. Piggott

There are no affiliations available

Personalised recommendations